Denali Therapeutics closed at $20.96 on Nov 4, up 7.76%, 23.0% below its 52-week closing high. Volume of 4.9M shares was 3.00× its 20-day average (well above normal).
Split-adjusted performance: +8.7% over one month, +2.7% over six months, +36.5% over one year.
In the quarter ended Jun 30, 2026, revenue was $3.60M, with a net margin of -3539.2%.
Short interest was 15.5M shares at the Oct 15 settlement (11.6% of float, 8.1 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DNLIDenali Therapeutics | $20.96 | +7.76% | +2.7% | — | −3539.2% | — | $3.35B | |
| TARSTarsus Pharmaceuticals | $69.07 | −4.91% | +6.7% | +63.9% | −343.5% | — | $3.23B | Compare |
| BEAMBeam Therapeutics | $27.79 | +5.54% | −14.1% | −94.2% | −25036.3% | — | $2.87B | Compare |
| IOVAIovance Biotherapeutics | $8.70 | −1.47% | +112.7% | +65.7% | −47.6% | — | $3.94B | Compare |
| RLAYRelay Therapeutics | $18.03 | +3.38% | +39.6% | −48.3% | −23916.3% | — | $3.95B | Compare |
| ADPTAdaptive Biotechnologies | $26.71 | +3.53% | +85.1% | +21.5% | −55.6% | — | $4.26B | Compare |
| ADMAADMA Biologics | $10.48 | −5.67% | +4.0% | +2.0% | 30.4% | 13.9 | $2.35B | Compare |
| VCELVericel | $45.48 | +10.68% | +23.7% | +22.5% | 2.8% | 96.2 | $2.33B | Compare |
| RXRXRecursion Pharmaceuticals | $3.88 | +5.43% | +13.1% | +258.5% | −641.6% | — | $2.32B | Compare |
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
